Shots:

• BioMed and Merck & Co (MSD outside the United States and Canada) signs an agreement and extends their ongoing collaboration for six joint research projects at BioMed X Innovation Center in Heidelberg- Germany
• The focus of the agreement is to concentrate on the role of intestinal epithelial barrier in the development and exacerbation of autoimmune diseases such as systemic lupus erythematosus (SLE) and multiple sclerosis (MS)
• BioMed X Innovation Center is a collaboration model at the interface between academia and industry and jointly work on pre-clinical research projects in the areas of biomedicine- molecular biology- cell biology and diagnostics

Click here to­ read full press release/ article

Ref: BioMed | Image: Merck